ReviewVaccines2022
The Cellular and Molecular Immunotherapy in Prostate Cancer.
Review in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Patient and Physician Perspectives on Prostate Cancer Data Presented at ASCO 2025.Oncology and therapy · 2026Article
- Review
- Decoding m6A: a new frontier in maternal-foetal immunology.Frontiers in immunology · 2026Review
- NGR-modified curcumin nanovesicles reverse immunotherapy resistance in triple-negative breast cancer via TLR9 and mTOR pathway modulation.Cell biology and toxicology · 2025Article
- DOCK3 orchestrates metastasis and immune microenvironment in prostate cancer.Frontiers in urology · 2025Article
- Article
- Article
- Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer.Molecular cancer · 2023Review
- Immunotherapy in Prostate Cancer: State of Art and New Therapeutic Perspectives.Current oncology (Toronto, Ont.) · 2023Review
- Unlocking the mystery associated with infertility and prostate cancer: an update.Medical oncology (Northwood, London, England) · 2023Review
- Role of Metabolism and Metabolic Pathways in Prostate Cancer.Metabolites · 2023Review
- Evaluation of CD47 in the Suppressive Tumor Microenvironment and Immunotherapy in Prostate Cancer.Journal of immunology research · 2023Article
- CHMP4C as a novel marker regulates prostate cancer progression through cycle pathways and contributes to immunotherapy.Frontiers in oncology · 2023Article
- Combination Immunotherapy in Prostate Cancer.Cancers · 2022Article
- Radiotherapy-Related Gene Signature in Prostate Cancer.Cancers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent history, immunotherapy has become a viable cancer therapeutic option. However, over many years, its tenets have changed, and it now comprises a range of cancer-focused immunotherapies. Clinical trials are currently looking into monotherapies or combinations of medicines that include immune checkpoint inhibitors (ICI), CART cells, DNA vaccines targeting viruses, and adoptive cellular therapy. According to ongoing studies, the discipline should progress by incorporating patient-tailored immunotherapy, immune checkpoint blockers, other immunotherapeutic medications, hormone therapy, radiotherapy, and chemotherapy. Despite significantly increasing morbidity, immunotherapy can intensify the therapeutic effect and enhance immune responses. The findings for the immunotherapy treatment of advanced prostate cancer (PCa) are compiled in this study, showing that is possible to investigate the current state of immunotherapy, covering new findings, PCa treatment techniques, and research perspectives in the field's unceasing evolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.